A Comprehensive Overview on BHF PROTECT TAVI & Cerebral Embolic Protection

In this exclusive interview, Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) speaks with Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK), Principal Investigator of the BHF PROTECT TAVI trial. This highly anticipated trial aims to provide groundbreaking insights into the field of Cerebral Embolic Protection (CEP) in TAVI.

In this interview, Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) and Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK) delve into the unique aspects of the BHF PROTECT TAVI trial, highlighting its distinguishing features compared to previous studies. They provide a comprehensive overview of the trial's current progress, shedding light on its outcomes, learnings, and potential clinical implications.

Moreover, the interview focuses on why the BHF PROTECT TAVI trial holds immense value for future considerations of CEP in TAVI. Prof Rajesh Kharbanda (Oxford University Hospitals NHS Foundation Trust, UK) and Dr Tessel Vossenberg (Medical Center Leeuwarden, Leeuwarden, NL) discuss the potential impact of this trial on daily clinical practice, particularly in assessing stroke risk during TAVI procedures.

Furthermore, the interview addresses the significance of CEP in TAVI patients, emphasising the potentially life-altering consequences of stroke and its associated costs. By exploring the current status of CEP and its impact on patients, this interview provides a comprehensive update on the subject.